S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Akebia Therapeutics Stock Forecast, Price & News

-0.15 (-5.62%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
3.48 million shs
Average Volume
2.53 million shs
Market Capitalization
$440.90 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Akebia Therapeutics logo

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$295.31 million
Book Value
$0.78 per share


Net Income
$-383.46 million
Net Margins
Pretax Margin




Free Float
Market Cap
$440.90 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.86 out of 5 stars

Medical Sector

776th out of 1,390 stocks

Pharmaceutical Preparations Industry

369th out of 668 stocks

Analyst Opinion: 3.2Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

Is Akebia Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Akebia Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKBA, but not buy additional shares or sell existing shares.
View analyst ratings for Akebia Therapeutics
or view top-rated stocks.

How has Akebia Therapeutics' stock been impacted by Coronavirus?

Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AKBA stock has decreased by 63.7% and is now trading at $2.52.
View which stocks have been most impacted by COVID-19

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Akebia Therapeutics

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.02. The biopharmaceutical company earned $48.76 million during the quarter, compared to the consensus estimate of $50.09 million. Akebia Therapeutics had a negative trailing twelve-month return on equity of 154.75% and a negative net margin of 142.00%. During the same period in the prior year, the company posted ($0.42) EPS.
View Akebia Therapeutics' earnings history

What price target have analysts set for AKBA?

3 equities research analysts have issued 12 month price targets for Akebia Therapeutics' shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Akebia Therapeutics' stock price to reach $9.00 in the next year. This suggests a possible upside of 257.1% from the stock's current price.
View analysts' price targets for Akebia Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the following people:

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics CEO John Butler on Glassdoor.com. John Butler has an approval rating of 97% among Akebia Therapeutics' employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.05%), Marshall Wace LLP (3.98%), Geode Capital Management LLC (1.85%), Dimensional Fund Advisors LP (1.20%), Morgan Stanley (0.84%) and Renaissance Technologies LLC (0.54%). Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke.
View institutional ownership trends for Akebia Therapeutics

Which major investors are selling Akebia Therapeutics stock?

AKBA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Morgan Stanley, Renaissance Technologies LLC, Citigroup Inc., Millennium Management LLC, Citadel Advisors LLC, and Jump Financial LLC. Company insiders that have sold Akebia Therapeutics company stock in the last year include John P Butler, Michel Dahan, Steven C Gilman, and Steven Keith Burke.
View insider buying and selling activity for Akebia Therapeutics
or view top insider-selling stocks.

Which major investors are buying Akebia Therapeutics stock?

AKBA stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, BlackRock Inc., UBS Group AG, Opaleye Management Inc., Geode Capital Management LLC, GSA Capital Partners LLP, Connor Clark & Lunn Investment Management Ltd., and Panagora Asset Management Inc..
View insider buying and selling activity for Akebia Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $2.52.

How much money does Akebia Therapeutics make?

Akebia Therapeutics has a market capitalization of $440.90 million and generates $295.31 million in revenue each year. The biopharmaceutical company earns $-383.46 million in net income (profit) each year or ($1.90) on an earnings per share basis.

How many employees does Akebia Therapeutics have?

Akebia Therapeutics employs 380 workers across the globe.

What is Akebia Therapeutics' official website?

The official website for Akebia Therapeutics is www.akebia.com.

Where are Akebia Therapeutics' headquarters?

Akebia Therapeutics is headquartered at 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at [email protected], or via fax at 617-871-2099.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.